Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VXB-251 in Older Adults for Prevention of LRTD Caused by RSV, hMPV, PIV3
NCT07295028Phase 1Active, not recruiting
- Sponsor
- Sanofi
- Start
- Nov 2025
- Primary completion
- Apr 2026
- Modality
- Viral Vector Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VXB-251 in pulmonary infection (8 arms), sponsored by Sanofi. Primary endpoints: Proportion of Participants With 1 or More Unsolicited Adverse Events at 1 month, Proportion of Participants With 1 or More Serious Adverse Events, AEs of Special Interest, and Premature Discontinuation Associated AEs at 1 month and 1 more. Started Nov 2025; status: active, not recruiting.
02
Drugs
VXB-251
03
Conditions
pulmonary infection
Beyond the preview
Go deeper on NCT07295028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07295028.